NeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. Wainwright


NeuBase Therapeutics Inc.’s filing revealed that its 10% Owner Symetryx Corp unloaded Company’s shares for reported $0.19 million on Sep 14. In the deal valued at $1.44 per share,129,108 shares were sold. As a result of this transaction, Symetryx Corp now holds 153,337 shares worth roughly $ 0.18 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Symetryx Corp sold 3,376 shares, generating $4,861 in total proceeds. Upon selling the shares at $1.44, the 10% Owner now owns 472,926 shares.

Before that, Symetryx Corp sold 128,847 shares. NeuBase Therapeutics Inc. shares valued at $197,136 were divested by the 10% Owner at a price of $1.53 per share. As a result of the transaction, Symetryx Corp now holds 476,302 shares, worth roughly $0.57 million.

H.C. Wainwright reiterated its NeuBase Therapeutics Inc. [NBSE] rating to a Buy in a research note published on Monday, February 12, 2021; the price target was $18. PT values the company’s stock at a premium of 93.33 to its Monday closing price.

Price Performance Review of NBSE

On Monday, NeuBase Therapeutics Inc. [NASDAQ:NBSE] saw its stock fall -7.69% to $1.20. On the same session, the stock had its day’s lowest price of $1.15, but rose to a high of $1.2612. Over the last five days, the stock has lost -8.40%. NeuBase Therapeutics Inc. shares have fallen nearly -68.45% since the year began. Nevertheless, the stocks have fallen -89.05% over the past one year. While a 52-week high of $11.05 was reached on 02/13/23, a 52-week low of $0.61 was recorded on 08/18/23. SMA at 50 days reached $1.2328, while 200 days put it at $3.2549. A total of 0.63 million shares were traded, compared to the trading of 10.66 million shares in the previous session.

Levels Of Support And Resistance For NBSE Stock

The 24-hour chart illustrates a support level at 1.1463, which if violated will result in even more drops to 1.0925. On the upside, there is a resistance level at 1.2575. A further resistance level may holdings at 1.3149. The Relative Strength Index (RSI) on the 14-day chart is 49.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0214, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.36%. Stochastics %K at 22.92% indicates the stock is a holding.

How much short interest is there in NeuBase Therapeutics Inc.?

A steep rise in short interest was recorded in NeuBase Therapeutics Inc. stocks on Aug 30, 2023, growing by 0.13 million shares to a total of 0.17 million shares. Yahoo Finance data shows the prior-month short interest on Jul 30, 2023 was 41130.0 shares. There was a rise of 76.15%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 5.74% of the overall stock float, the days-to-cover ratio (short ratio) rose to 0.29.

NeuBase Therapeutics Inc. [NBSE] – Who Are The Largest Shareholders?

In filings from Armistice Capital LLC, it is revealed that the company now owns 166,174 shares, or roughly 7.03% of the outstanding NBSE shares.. At present, The Vanguard Group, Inc. is holding 18,981 shares valued at $18412.0. Jacob Asset Management of New Yor owned 15,655 shares of the company at the time of its most recent 13F filing, worth $15185.0.

According to FactSet, NeuBase Therapeutics Inc.’s share price will average $200.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 15284.62 percent from its previous closing price of $1.30. Analysts expect NeuBase Therapeutics Inc. stock to reach the higher price of $200.00, while the lowest price estimate is $200.00. However, 1 analyst have rated NBSE stock as a Hold in their predictions for 2023.


Please enter your comment!
Please enter your name here